ELOVL2 antibody (AA 247-296)
Quick Overview for ELOVL2 antibody (AA 247-296) (ABIN7266927)
Target
See all ELOVL2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 247-296
-
Purpose
- ELOVL2 Rabbit pAb
-
Sequence
- ILFLNFYVQT YRKKPMKKDM QEPPAGKEVK NGFSKAYFTA ANGVMNKKAQ
-
Cross-Reactivity
- Human, Rat
-
Characteristics
- Polyclonal Antibodies
-
Purification
- Affinity purification
-
Immunogen
- Recombinant fusion protein containing a sequence corresponding to amino acids 247-296 of human ELOVL2 (NP_060240.3).
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB,1:500 - 1:2000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- ELOVL2 (ELOVL Fatty Acid Elongase 2 (ELOVL2))
-
Alternative Name
- ELOVL2
-
Background
- Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs per cycle. Condensing enzyme that catalyzes the synthesis of polyunsaturated very long chain fatty acid (C20- and C22-PUFA, acting specifically toward polyunsaturated acyl-CoA with the higher activity toward C20:4(n-6 acyl-CoA. May participate in the production of polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators.,SSC2,ELOVL2,Cancer,Signal Transduction,Endocrine & Metabolism,Lipid Metabolism,Endocrine and metabolic diseases,Diabetes,Cardiovascular,Heart,Lipids,Fatty Acids,Cardiovascular diseases,Heart disease,ELOVL2
-
Gene ID
- 54898
-
UniProt
- Q9NXB9
Target
-